Navigation Links
Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
Date:2/13/2009

    New manufacturing facility opening in Second Quarter

TORONTO, Feb. 13 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (TSX:MBX) said today that despite a challenging year for the biopharmaceutical industry, it has maintained its focus and continued its advance toward the ultimate goal of sustained profitability. The Company was announcing results for the first quarter ended December 31, 2008.

In a news release today, William J. Gastle, CEO of Microbix said "the Company has improved the fundamentals of its core business and we are approaching major milestones in our product pipeline. We are waiting for the FDA to authorize release of Kinlytic inventory, our Urokinase product, we are in discussions with potential pharma partners for our Hunan (China) influenza vaccine business and we expect to provide guidance on the SST program as we near the end of the expanded sex specific protein investigation described in 2008."

    First Quarter Highlights

    Core Business

Growth was robust in the first quarter with sales improving over 50 per cent compared to the same quarter last year. "We exceeded our sales target in the first quarter," Mr. Gastle continued "and we are on a path to meet or exceed projections for this fiscal year. The Company will open its new facility in Mississauga, Ontario in March 2009 with significantly improved capacity.

VIRUSMAX(TM)

The Company is collaborating with a major firm to evaluate VIRUSMAX in their influenza vaccine manufacturing process in the second quarter. Preliminary results were promising and the evaluation has moved to the next phase at the partner's manufacturing facility.

We are pleased with the arrangement to form a manufacturing joint venture agreement to build and operate an influenza vaccine plant in China based on VIRUSMAX. We are making solid progress towards completing the pre-conditions that hav
'/>"/>

SOURCE Microbix Biosystems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
2. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
3. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
4. Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
5. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
6. Max Muscle Introduces First-Ever Probiotics Protein Bar
7. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
8. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
9. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
10. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
11. World's First Website for Patients to Share Diagnostic-Quality Medical Images
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... SOUTH SAN FRANCISCO, Calif., Aug. 27 Poniard,Pharmaceuticals, ... focused,on oncology, today announced that Jerry McMahon, Ph.D., ... in early September: The Thomas Weisel Partners ... p.m. Eastern time at the Four Seasons Hotel ...
... Aug. 27 Sanofi-aventis,U.S. launched today a new ... (oxaliplatin injection) for patients who have,adjuvant stage III ... to offer more convenience, efficiency and safety in ... had been,available in 50 mg and 100 mg ...
... Diabetes Meta-Database to Quantify Competitive Treatment Landscape and Accelerate ... ... MOUNTAIN VIEW, Calif., Aug. 27 Pharsight,Corporation (OTC Bulletin Board: ... clinical drug development, today,announced that it has licensed its public-source ...
Cached Biology Technology:Poniard Pharmaceuticals Announces Participation in Upcoming Conferences 2New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 2New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 3New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 4New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 5New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 6New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 7Pharsight Achieves First License Sale for Public-Source Database 2Pharsight Achieves First License Sale for Public-Source Database 3
(Date:7/10/2014)... teens living with a cardiac pacemaker, a low sense ... life, reports a study in the July ... official journal of the Society for Developmental and ... Lippincott Williams & Wilkins , a part of ... as a protective factor against lower health-related quality of ...
(Date:7/10/2014)... used to control everyday household items such as washing ... for conservation, a new study has claimed., As part ... scientists and mathematicians, including those from the University of ... engineering, could be replicated in the natural world to ... ,integral control, - in essence a built-in feedback control ...
(Date:7/10/2014)... Consuming a whole fresh avocado with either an orange-colored ... carotenoid (alpha- and beta-carotene) absorption and conversion of these ... to new research (1) published in The ... A is involved in reproductive health and growth promotion; ... has antioxidant properties. Provitamin A carotenoids, like alpha- and ...
Breaking Biology News(10 mins):For children with pacemakers, 'self-competence' affects quality of life 2Feedback control could be key to robust conservation management 2New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2
... Kolls, Professor and Chairman of Genetics at the LSU Health ... a $2.1 million grant over five years by the National ... Health to further his work on a discovery that plays ... Bacterial pneumonia is an important clinical problem and defense mechanisms ...
... a first-of-its-kind cloth that releases nitric oxide gas an ... a wrap to help preserve organs harvested for transplantation. The ... bi-weekly journal. Kenneth Balkus and Harvey Liu note in ... flow and regulates a range of other body functions. Scientists ...
... drugs are embracing new tactics to deal with an ... far from being won. That,s the focus of an ... Engineering News (C&EN) , ACS, weekly newsmagazine. Counterfeiting ploys ... to identify their products as genuine. C&EN Associate ...
Cached Biology News:LSUHSC awarded multi-million dollar grant to reduce pneumonia 2
... ESGRO Complete Derivation Kit is ... ES cells from delayed blastocysts in ... Clonal ... Delayed Blastocyst Incubation Medium Trypsin ...
Template and primers for preparation of internal control spots...
Reusble. Uses in conjunction with the Apoptotic Cell Isolation Kit....
ANTI K. AEROGENES...
Biology Products: